Evidence map›Paper›PMID 34487434›Full record

ArticleBioconjugate chemistry2021

Synthetic Pept-Ins as a Generic Amyloid-Like Aggregation-Based Platform for

Maxime Siemons, Kaat Luyten, Ladan Khodaparast, Laleh Khodaparast, Joan Lecina, Filip Claes, Rodrigo Gallardo, Michel Koole, Meine Ramakers, Joost Schymkowitz and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioconjugate chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Mechanisms and pathology of protein misfolding and aggregation.Nature reviews. Molecular cell biology · 2023
    Review
  2. Review
  3. Exploiting the intrinsic misfolding propensity of the KRAS oncoprotein.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Maxime SiemonsLaboratory for Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, BE3000 Leuven, Belgium.
Kaat LuytenLaboratory for Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, BE3000 Leuven, Belgium.
Ladan KhodaparastSwitch Laboratory, VIB Center for Brain and Disease Research, Leuven, Belgium and Switch Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, BE3000 Leuven, Belgium.
Laleh KhodaparastSwitch Laboratory, VIB Center for Brain and Disease Research, Leuven, Belgium and Switch Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, BE3000 Leuven, Belgium.
Joan LecinaLaboratory for Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, BE3000 Leuven, Belgium.
Filip ClaesSwitch Laboratory, VIB Center for Brain and Disease Research, Leuven, Belgium and Switch Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, BE3000 Leuven, Belgium.
Rodrigo GallardoSwitch Laboratory, VIB Center for Brain and Disease Research, Leuven, Belgium and Switch Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, BE3000 Leuven, Belgium.
Michel KooleNuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven and UZ Leuven, BE3000 Leuven, Belgium.
Meine RamakersSwitch Laboratory, VIB Center for Brain and Disease Research, Leuven, Belgium and Switch Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, BE3000 Leuven, Belgium.
Joost SchymkowitzSwitch Laboratory, VIB Center for Brain and Disease Research, Leuven, Belgium and Switch Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, BE3000 Leuven, Belgium.
Guy BormansLaboratory for Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, BE3000 Leuven, Belgium.ORCID 0000-0002-0335-7190
Frederic RousseauSwitch Laboratory, VIB Center for Brain and Disease Research, Leuven, Belgium and Switch Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, BE3000 Leuven, Belgium.
VIB-KU Leuven Center for Brain & Disease Research · BEKU Leuven · BEUniversitair Ziekenhuis Leuven · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amyloid-like aggregation of proteins is induced by short amyloidogenic sequence segments within a specific protein sequence resulting in self-assembly into β-sheets. We recently validated a technology platform in which synthetic amyloid peptides ("Pept-ins") containing a specific aggregation-prone region (APR) are used to induce specific functional knockdown of the target protein from which the APR was derived, including bacterial, viral, and mammalian cell proteins. In this work, we investigated if Pept-ins can be used as vector probes for

Indexed as

Positron-Emission TomographyAcetatesAmyloidAnimalsEscherichia coliGallium RadioisotopesHeterocyclic Compounds, 1-RingHumansMiceProtein AggregatesRadiopharmaceuticals1-(1,3-carboxypropyl)-4,7-carboxymethyl-1,4,7-triazacyclononaneAcetatesAmyloidGallium RadioisotopesHeterocyclic Compounds, 1-RingProtein AggregatesRadiopharmaceuticals

Identifiers

PMID34487434
PMCPMC8447941
OpenAlexW3198681671

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.